• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 americanpharmaceuticalreview
    September 20, 2018
    OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL). OBI-3424 is a first in class DNA alkylating cancer therapeutic agent targeting
  • OBI Pharma gets FDA clearance for new drug application biospectrumasia
    April 20, 2018
    OBI-3424 is a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1C3 (AKR1C3)
  • Abzena and OBI Pharma sign licence deal for ThioBridge technology pharmaceutical-technology
    July 13, 2017
    UK-based life sciences group Abzena has signed a licensing contract and a master service and clinical supply agreement with Taiwan, Chinaese biopharmaceutical company OBI Pharma to enable process development and manufacturing using ThioBridge.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service